title: Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients.
abstract: Lowering blood pressure is not totally effective in preventing the atherosclerotic complications of systemic hypertension. In hypertensive patients both platelet hyperaggregation and dyslipidemia have been suggested as important risk factors. The effect of 8 weeks' treatment with ketanserin on blood pressure, serum lipid parameters (cholesterol, triglycerides, LDL, HDL-C, apolipoprotein A1 and B) and platelet aggregation, induced by collagen, ADP, arachidonic acid, was evaluated in 10 patients with essential hypertension. Ketanserin was effective in lowering blood pressure in all patients, 6 of whom became normotensive. Both CHOL and TG levels and APO B were significantly reduced, whereas HDL-C and APO A1 were significantly increased after treatment. These results might be attributed to the antagonistic activity of ketanserin on alpha-1 adrenoceptors with a consequent inhibition of phosphodiesterase. Platelet aggregation, after stimulation with collagen and arachidonic acid, was significantly reduced secondary to the inhibition of intraplatelet serotonin synthesis and release. These results suggest that keranserin is effective in reducing blood pressure and in achieving normal serum lipid pattern and platelet aggregation. Therefore, this drug might be helpful in controlling the main risk factors for cardiovascular damage.
authors: Divisione Clinicizzata di Nefrologia, Istituti Ospitalieri, Verona, Italy.
authors: C
authors: C
authors: Loschiavo
authors: E
authors: E
authors: Valvo
authors: V
authors: V
authors: Bedogna
authors: P
authors: P
authors: Casagrande
authors: M S
authors: MS
authors: Graziani
authors: M
authors: M
authors: Nicoli
authors: G
authors: G
authors: Maschio
mesh_terms: D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood*; D007650:Ketanserin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood*
chemical_list: D001053:Apolipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010975:Platelet Aggregation Inhibitors; D014280:Triglycerides; D002784:Cholesterol; D007650:Ketanserin